Table 1.
Patient Characteristics and Response
| Patient | Age | Sex | M Stage | LDH Level (>ULN) | Prior Therapy | ECOG | Tissue Type | No. IL-2 Doses | No. Nivo Doses | Response at 12 weeks after ACT | Response at 1 year after ACT | Notes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cohort 1 | ||||||||||||
| 1 | 67 | M | M1c | 1.0X | IFN, Adj | 0 | SQ | 1 | 18 | PR | PR | |
| 2 | 46 | F | M1c | 8.4X | IFN, Adj, D/T | 1 | SQ | NT | NA | PD | PD | Progressed prior to ACT |
| 3 | 54 | M | M1b | <1X | None | 0 | LN | 6 | 2 | PD | PD | |
| 4 | 37 | F | M1c | <1X | None | 0 | SQ | 5 | 5 | PD | PD | |
| 5 | 44 | M | M1c | <1X | Adj, Ipi | 1 | LN | 1 | 1 | PD | PD | Removed: Noncompliance |
| 6 | 55 | F | M1c | <1X | Adj, Ipi | 0 | SQ | 6 | 11 | SD | PD | |
| Cohort 2 | ||||||||||||
| 7 | 52 | F | M1c | 2.4X | None | 1 | LN & Breast | 6 | 8 | SD | PD | |
| 8 | 50 | M | M1a | <1X | D/T, V/C | 0 | LN | 6 | 8 | SD | PD | |
| 9 | 45 | M | M1a | <1X | None | 1 | NA | NT | 2 | PR | PR | Response to Nivolumab |
| 10 | 68 | F | M1c | 1.0X | None | 0 | SQ & LN | 6 | 19 | PR | PR | |
| 11 | 54 | M | M1c | 1.1X | None | 0 | LN | 4 | 21 | PR | PR | |
Nivo= Nivolumab; NA= Not Applicable; NT= Not Treated; SQ= subcutaneous disease, LN= nodal disease; LDH Level= fold above upper limit of normal (>ULN) IFN = Interferon; Adj = Adjuvant; D/T=Dabrafenib/Trametinib; V/C= Vemurafenib/Cobimetinib